RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2/Phase 3

Registered title, quoted from ClinicalTrials.gov

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  2. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07226999, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).

    Inclusion criterion 1

  3. Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC

    Inclusion criterion 3

  4. For Phase 2 (except the Part B doublet cohort) and Phase 3: no prior systemic therapy for ES-SCLC. Participants who received 1 cycle of chemotherapy (without immunotherapy) for management of life-threatening ES-SCLC are eligible if all other criteria are met.

    Inclusion criterion 2

  5. Eastern Cooperative Oncology Group performance status of 0 or 1.

    Inclusion criterion 5

  6. Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.

    Inclusion criterion 4

  7. History of another malignancy within 2 years, except for certain low-risk cancers.

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07226999, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • For Phase 2 (except the Part B doublet cohort) and Phase 3: no prior systemic therapy for ES-SCLC. Participants who received 1 cycle of chemotherapy (without immunotherapy) for management of life-threatening ES-SCLC are eligible if all other criteria are met.
  • Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
  • Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.
  • Eastern Cooperative Oncology Group performance status of 0 or 1.
  • Adequate organ function

Exclusion Criteria:

  • Active central nervous system (CNS) lesions, including brainstem, meningeal, or spinal cord metastases/compression. Participants with adequately treated and stable brain metastases, or certain untreated asymptomatic brain metastases, may be eligible.
  • Leptomeningeal disease
  • Clinically significant risk of hemorrhage or fistula, including radiographic evidence of major blood vessel invasion/infiltration or tumor invasion of critical organs.
  • History of another malignancy within 2 years, except for certain low-risk cancers.
  • Active autoimmune diseases requiring systemic treatment within the past 2 years
  • Evidence of non-infectious/drug-induced interstitial lung disease (ILD) or pneumonitis, or certain severe pulmonary conditions.
  • Uncontrolled significant comorbidities within 6 months before study treatment

Quoted from ClinicalTrials.gov, NCT07226999, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07226999, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07226999